Cytokinetics, Inc. (CYTK)
| Market Cap | 3.37B |
| Revenue (ttm) | 65.03M |
| Net Income (ttm) | -257.66M |
| Shares Out | 85.65M |
| EPS (ttm) | -2.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,718 |
| Open | 41.02 |
| Previous Close | 42.15 |
| Day's Range | 39.21 - 42.16 |
| 52-Week Range | 17.72 - 47.90 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 60.01 (+52.5%) |
| Earnings Date | May 4, 2022 |
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase II...
Financial Performance
In 2021, Cytokinetics's revenue was $70.43 million, an increase of 26.15% compared to the previous year's $55.83 million. Losses were -$215.31 million, 69.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is 60.01, which is an increase of 52.52% from the latest price.
News
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in t...
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to presen...
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
FDA Plans to Convene Advisory Committee Meeting FDA Plans to Convene Advisory Committee Meeting
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International ...
Mizuho: these two biotech stocks are worth buying right now
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics Reports First Quarter 2022 Financial Results
Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022
Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Tuesday, May 10, 2022 at 1...
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...
Cytokinetics to Announce First Quarter Results on May 4, 2022
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM E...
Cytokinetics Announces Changes to Board of Directors
L. Patrick Gage, Ph.D. to Retire from Board
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to part...
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American Colleg...
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual S...
Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Disopyramide Aficamten Reduced LVOT Gradients and Improved NY...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2022 it granted stock options to purchase an aggregate of 165,...
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Sessi...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific ...
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pres...
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the...
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics Reports Fourth Quarter 2021 Financial Results
Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstr...
Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capaci...
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and...
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-yea...
Cytokinetics Announces Topline Results From METEORIC-HF
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction